Purchase Order 75N92019P00156
- Not listed
- This is a firm fixed-price delivery order awarded by the National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), to Illumina, Inc., a biotechnology company specializing in genetic sequencing and genomic analysis technologies. The $48,994.05 contract is for the procurement of an Illumina MiSeq I100 sequencing system and associated reagents and services, to support high-quality DNA sequencing and genomic research at NHLBI. The contract has an ultimate...
- This is a firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Illumina, Inc. for the purchase of a MiSeq System sequencing platform. The contract has a ceiling value of $95,931.00 and a completion date of August 21, 2014. Illumina is a manufacturer of sequencing and genomic analysis instruments and reagents that has previously provided such products and services to various federal...
- This is a firm fixed price purchase order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Illumina, Inc. The contract has a ceiling value of $646,396.36 and no set-aside designation. Illumina, a manufacturer of sequencing and array-based genomic analysis solutions, will provide a range of sequencing systems, reagents, and services to support NHLBI's research and diagnostics needs. Illumina has a history of...
- This $95,931.00 firm fixed price purchase order was awarded by the National Institute of Environmental Health Sciences (NIEHS), a civilian federal agency, to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and related products. The contract is for the provision of a MiSeq System, a genetic analysis platform used in life science research, applied markets, and molecular diagnostics. Illumina has a history of providing sequencing systems and consumables to support...
- This is a firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Illumina, Inc. for the provision of a MiSeq benchtop DNA sequencer system. The total ceiling value of the contract is $119,937.50, with a performance period ending on December 2, 2013. The contract does not have any set-aside designation. Illumina, a manufacturer and provider of sequencing and array-based solutions,...
- This $95,931 firm-fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Illumina, Inc. for a MiSeq High Throughput Sequencer System. The award did not have a set-aside designation. The MiSeq system will be used in NIAID's Laboratory of Immunoregulation and must be fully compatible with Illumina's existing on-site software, kits, and reagents. Illumina has a history of providing...
- This is a firm-fixed-price purchase order awarded by the Naval Medical Research Command to Illumina, Inc., a for-profit manufacturer of genomic sequencing technologies. The requirement is for a MiSeq i100 Plus System, a specialized DNA/RNA sequencing instrument. The $90,997.20 contract has an ultimate completion date of July 30, 2025. Illumina is a prime contractor providing a range of genomic sequencing platforms, reagents, consumables, and maintenance services to multiple federal civilian...
- This is a firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), to Illumina, Inc. for the provision of an MiSeq sequencing system. The total ceiling value of the contract is $126,250.00. There is no set-aside designation associated with this award. Through past prime federal contract awards, Illumina has provided a range of genomic sequencing instruments, reagents, and related...
- This is a $15,849.80 firm fixed price purchase order awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Illumina, Inc. The contract is for the maintenance of a MiSeq M06580 DNA sequencing instrument and associated services. The contract has a period of performance through September 11, 2026. Illumina, a manufacturer of genomic sequencing technologies, has been awarded multiple federal contracts and grants by the NIH, Centers...
- This firm fixed-price purchase order was awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for a MiSeq support plan. The $15,388.08 contract is intended to ensure optimal performance and reliability of the MiSeq system to support genomic research and clinical applications at the NHLBI DNA Sequencing and Genomics Core. Illumina, a manufacturer of sequencing and array-based solutions, has previously provided...
This is a firm fixed price purchase order awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for the acquisition of an Illumina MiSeq System. The contract has a ceiling value of $95,931.00 and a completion date of August 31, 2019. Illumina is a manufacturer of genetic sequencing and analysis instruments and reagents, and has received past prime contract awards from various federal agencies to support their genomic sequencing and analysis needs. This purchase order does not have a set-aside designation. Illumina has also held an Indefinite Delivery Contract with the Department of the Navy Bureau of Medicine and Surgery to provide reagents and controls for their MiSeq, iSeq, NextSeq and NovaSeq6000 sequencing platforms used for biological threat characterization.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $95.9k | 5/29/19 |